Please login to the form below

Not currently logged in
Email:
Password:

Sigma-Tau Pharmaceuticals appoints Dave Lemus chief operating officer

He takes over from Gregg Lapointe who has resigned

Dave Lemus has been appointed chief operating officer at Sigma-Tau Pharmaceuticals.

He joined the US rare diseases company in July 2011 as VP, finance and in his new role he takes over from Gregg Lapointe who has resigned.

President of Sigma-Tau Pharmaceuticals Professor Trevor Jones said: "We are delighted to appoint Dave to lead our efforts to expand the world-class rare disease business we have established in the US.

“Dave brings a wealth of relevant pharmaceutical and biotech experience from both the US and Europe. His appointment will serve to further strengthen our unwavering mission to serve the needs of rare disease patients."

Prior to joining Sigma-Tau Lemus was chief financial officer at German biotech company MorphoSys, where he launched Germany's first-ever biotechnology IPO in 1999.

Before this he held a variety of senior management roles at Hoffmann-La Roche and Lindt in Switzerland.

12th March 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 700 experts delivering world-class...

Latest intelligence

Healthcare in a lockdown
Even if patients are getting enough care during the COVID-19 pandemic, are they getting the right care?...
Love in the Time of Coronavirus
Having gone through 4 stages of coping with covid-19: first disbelief, then humour, then creative ways to deal with isolation, and finally the tragic realisation that lives are being lost...
The other side of … multiple sclerosis
No good comes from excluding patients from having a say in their own care. In fact, improving activation (& outcomes) demands it....

Infographics